Current Collaborations

“Qu creates an environment where people and ideas connect to drive true innovation.”

Leading edge research

Qu Biologics recognizes the substantial benefit gained from synergistic research collaborations with industry and academia. Collaborations provide access to technological advances and new scientific breakthroughs, leading to faster progress towards the goal of finding safe and effective treatments and cures.

Qu scientist_fumehoodWIDErightspace

Qu Biologics has teamed up with a number of universities to collaborate on research projects. Collaborations include:

University of British Columbia, Dr. Bruce Vallance – Dr. Bruce Vallance is an expert in inflammatory bowel disease, and is recognized for his expertise in modeling of inflammatory bowel disease and enteric bacterial infection. In collaboration with Qu Biologics and with funding awarded through MITACS, Dr. Vallance’s team is studying the therapeutic effects of Qu Biologics’ SSI treatment for inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in mouse models that mimics the underlying innate immune system defect and chronic bacterial infection associated with these diseases.

Geisel School of Medicine, Dartmouth College, Dr. David Mullins – Qu’s collaboration with Dartmouth College researches tumour targeting and the range of mechanisms by which Qu Biologics’ Site Specific Immunomodulator (SSI) therapy leads to the killing of cancer cells. These studies are conducted at the laboratory of Dr. David Mullins at the Norris Cotton Cancer Center and the Geisel School of Medicine at Dartmouth in Lebanon, New Hampshire.

University of Ottawa, Dr. Adam Shuhendler – Qu Biologics is currently collaborating with Dr. Adam Shuhendler to investigate the trafficking of Site Specific Immunomodulators (SSIs) throughout the body. Dr. Shuhendler is an expert is using advanced imaging techniques, including positron emission tomography (PET) and magnetic resonance imaging (MRI), to understand the fate of biological molecules in the body. Dr. Shuhendler, in partnership with Qu Biologics, has been awarded an Engage Grant from the Natural Sciences and Engineering Research Council (NSERC) of Canada for this work.

 

Past events:


Past events: